pTVG-HP DNA Vaccine Shows Long-Term Survival Benefit in Recurrent Prostate Cancer

/in , , /by

Long-term follow-up from a randomized phase 2 trial suggests that the DNA vaccine pTVG-HP (MVI-816) may significantly extend overall survival in men with PSA-recurrent, non-metastatic, castration-sensitive prostate cancer. The findings are particularly notable because the vaccine did not improve the study’s original primary endpoint of 2-year metastasis-free survival. The trial enrolled 99 men whose prostate […]

Read more

Darolutamide Linked to Cognitive Benefit Over Enzalutamide in Prostate Cancer

/in , , , , /by

Darolutamide (Nubeqa) caused significantly less cognitive decline than enzalutamide (Xtandi) over 24 weeks in men with advanced prostate cancer, according to results from the phase 2 ARACOG trial, which are scheduled to be presented at the 2026 ASCO Annual Meeting. The findings represent the first randomized, prospective head-to-head comparison of the cognitive effects of two […]

Read more

Darolutamide Monotherapy in ARAMON Trial: 52-Week Results in Non-Metastatic or Oligometastatic CSPC

/in , , , , /by

A new study called ARAMON shows promising results for using darolutamide alone to treat non-metastatic or oligometastatic castration-sensitive prostate cancer (CSPC), as known as androgen pathway modulator sensitive (APMS), in men who have biochemical recurrence after surgery or radiation. This phase 2 trial enrolled 23 evaluable patients with PSA ≥0.2 ng/mL post-prostatectomy or ≥2 ng/mL […]

Read more

Alliance A222001 Phase 2 Trial: Oxybutynin Looks Promising for Hot Flashes in Men Under ADT

/in , , , , /by

The Alliance A222001 study, published in the Journal of Clinical Oncology in January 2026, found that oxybutynin, a drug typically used to treat overactive bladder, significantly reduces hot flashes in men receiving androgen-deprivation therapy (ADT), with improvements occurring within the first week of treatment and sustained throughout the study period. The findings could reshape how […]

Read more

Low‑Dose Naltrexone for ADT‑Related Fatigue in Prostate Cancer

/in , , , , /by

A new trial will test whether nightly low‑dose naltrexone (3 mg) reduces fatigue in men with prostate cancer receiving androgen‑deprivation therapy (ADT), while concurrently profiling mitochondrial, inflammatory, and oxidative stress pathways that may drive cancer‑related fatigue in this setting. The single‑arm University of Arkansas study plans to enroll 60 men over 30 months, using FACIT‑F […]

Read more